MedTrace Logo

Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer

NCT00087087 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2014-02-14

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer.

Conditions

Interventions

DRUG

pemetrexed disodium

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Gynecologic Oncology Group

    lead NETWORK

Principal Investigators

  • David S. Miller, MD · Simmons Cancer Center

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00087087 on ClinicalTrials.gov